Company Overview and News

0
An evening walk down Dalal Street: Global cues lift Sensex 277 pts ahead of Q1FY19 earnings

2018-07-09 moneycontrol
Equity benchmarks began the week on a strong note on Monday, gaining over 0.70 percent on positive global cues and ahead of June quarter earnings. Banks and metals stocks, and Reliance Industries, L&T and Infosys drove the market higher.
DB 500325 500820 JIPKY RELIANCE KTKBANK 532538 ASIANPAINT 532187 505283 RIGD UCLQY 500493 BHARATFORG RLNIY YESBANK INDUSINDBK KIRLPNU JPASSOCIAT UCLQF 532648 YYBKY STRTECH ULTRACEMCO 532532 SRLRY 532652 532374

0
Kirloskar Pneumatic surges 8% as board to consider stock split

2018-07-09 moneycontrol
Share price of Kirloskar Pneumatic Company surged 8 percent intraday Monday as company to consider stock split on July 24.
505283 KIRLPNU

14
Axis Bank, YES Bank, SBI Life results

2018-04-25 thehindubusinessline
Thursday will see a host of prominent companies, such as AB Money, Accelya Kale, AU Small Finance, Automotive Stamplings, Axis Bank, Biocon, Coromandel Engineering, Essel Propack, HIL, Indian Energy Exchange, JL Morison, Kirloskar Pneumatic, Oil Country, Rallis India, Reliance Capital, SBI Life Insurance, Shriram City Union Finance, Supreme Industries, Tata Elxsi, Tata Metaliks and YES Bank declaring their quarter and full-year results for the period ended March 2018.
500408 RALLIS 532215 SPMWY 505283 SHRIRAMCIT AXISBANK SUPREMEIND 500355 500135 500111 YESBANK AXB RELCAPITAL TATAMETALI ESSELPRO KIRLPNU 513434 532648 YYBKY 533167 COROENGG AXBKY 532498 AXBA STS TATAELXSI 509930

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...